What level of response would you anticipate with the liposomal irinotecan regimen for this patient, based on data published in The Lancet earlier this year?

There is a RECIST response rate that’s seen and that’s in the 10% plus range, which I think is meaningful. We see more patients with stable disease, but we do see overt responses in the second-line setting and that always catches our eye in this disease to see actual tumor regression beyond a frontline setting. With regard to 5-FU and leucovorin, the control arm had a very low single-digit response rate, so there was a significant response difference in outcome. The other parameters that would support that were the progression-free survival advantage that was identified and CA19-9 improvements. The data were consistent in terms of indicating that there was a value over 5-FU and leucovorin for the triplet combination.